|
Clear Cell Carcinoma
Clear-cell carcinoma, also known as clear-cell adenocarcinoma and mesonephroma, is an epithelial-cell-derived carcinoma characterized by the presence of clear cells observed during histological, diagnostic assessment. This form of cancer is classified as a rare cancer with an incidence of 4.8% in white patients, 3.1% in black patients, and 11.1% in Asian patients. Clear-cell carcinoma may arise in multiple tissue types including the kidney ( clear-cell renal-cell carcinoma), ovary ( ovarian clear-cell carcinoma), uterus (uterine clear-cell carcinoma) or gastrointestinal tract (colorectal clear-cell carcinoma). Treatment options for clear cell carcinoma vary by the tissue type affected. It may include a combination of chemotherapy (paclitaxel and carboplatin or irinotecan plus cisplatin) and surgical resection in ovarian clear-cell carcinoma; debulking or resection paired with chemotherapy (cisplatin) in ovarian clear-cell carcinoma; cytokine therapy (IL-2, interferon), kinase i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Clear-cell Adenocarcinoma
Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear cells. Types include: * Clear-cell adenocarcinoma of the vagina * Clear-cell ovarian carcinoma * Uterine clear-cell carcinoma Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is aggressive and has high recurrence rate. Like uterine papillary serous carcinoma CC does not develop from endometrial ... * Clear-cell adenocarcinoma of the lung (which is a type of Clear-cell carcinoma of the lung) See also * References External links Carcinoma {{oncology-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ovarian Clear-cell Carcinoma
Ovarian clear-cell carcinoma, or clear-cell carcinoma of the ovary, also called ovarian clear-cell adenocarcinoma, is one of several subtypes of ovarian carcinoma – a subtype of epithelial ovarian cancer, in contrast to non-epithelial cancers. According to research, most ovarian cancers start at the epithelial layer which is the lining of the ovary. Within this epithelial group ovarian clear-cell carcinoma makes up 5–10%. It was recognized as a separate category of ovarian cancer by the World Health Organization in 1973. Its incidence rate differs across various ethnic groups. Reports from the United States show that the highest rates are among Asians with 11.1% versus whites with 4.8% and blacks at 3.1%. These numbers are consistent with the finding that although clear-cell carcinomas are rare in Western countries they are much more common in parts of Asia. Background There are two subtypes of ovarian carcinoma – epithelial and nonepithelial; ovarian clear-cell carcinoma ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Clear-cell Tumor
{{disambig ...
Clear-cell tumor (any with clear cells) can refer to: * clear-cell sarcoma, including ** clear-cell sarcoma of the kidney * clear-cell carcinoma, mostly ** clear-cell adenocarcinoma Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear cells. Types include: * Clear-cell adenocarcinoma of the vagina * Clear-cell ovarian carcinoma * Uterine clear-cell carcinoma Uterine clear-cell carcinoma (CC) is a rare ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Carboplatin
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein. Side effects generally occur. Common side effects include low blood cell levels, nausea, and electrolyte problems. Other serious side effects include allergic reactions and increased future risk of another cancer. Use during pregnancy may result in harm to the baby. Carboplatin is in the platinum-based antineoplastic family of medications and works by interfering with duplication of DNA. Carboplatin was patented in 1972 and approved for medical use in 1989. It is on the World Health Organization's List of Essential Medicines. Medical uses Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used fo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pazopanib
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide. Medical uses It is approved by numerous regulatory administrations worldwide, including the US Food and Drug Administration (FDA) (19 October 2009), the European Union's European Medicines Agency (EMA) (14 June 2010), the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) (14 June 2010) and Australia's Therapeutic Goods Administration (TGA) (30 June 2010), for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. In Australia and New Zealand, it is subsidised under the Pharmaceutical Benefits Scheme (PBS) and by Pharmac respectively, under a number of co ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sorafenib
Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer ( hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma. Mechanism of action Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases. Of the RAF kinases, sorafenib is more selective for c-Raf than B-RAF. (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.) Sorafenib treatment induces autophagy, which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, sorafenib is also a potent soluble epoxide hydrolase inhibitor and this activity likely reduces the severity of its adverse effects. Medical uses Sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thy ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sunitinib
Sunitinib, sold under the brand name Sutent, is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. As of August 2021, sunitinib is available as a generic medicine in the US. Medical uses Gastrointestinal stromal tumor Like RCC, GIST does not generally respond to standard chemotherapy or radiation. Imatinib was the first cancer agent proven effective for metastatic GIST and represented a major development in the treatment of this rare but challenging disease. However, approximately 20% of patients do not respond to imatinib (early or primary resistance), and among those who do respond initially, 50% develop secondary imatinib resistance and disease progression within t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Temsirolimus
Temsirolimus, sold under the brand name Torisel, is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in May 2007, and was also approved by the European Medicines Agency (EMA) in November 2007. It is a derivative and prodrug of sirolimus. Mechanism of action Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells. Though temsirolimus shows activity on its own, it is also known to be converted to sirolimus (rapamycin) in vivo; therefore, its activity may be more attributed to its metabolite rather than the prodrug itself (despite claims to the contrary by the manufacturer). Treatment with temsirolimus leads to cell cycle arrest in the G1 phase, and also inhibits tumor angiogenesis by reducing synthesis of VEGF. mTOR (mammalian target of rapamycin) is a kinase enzyme i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Debulking
Debulking is the reduction of as much of the bulk (volume) of a tumour without the intention of a complete eradication. It is usually achieved by surgical removal. When performed for curative intent, it is a different procedure, which is called surgical debulking of tumors is known as cytoreduction or cytoreductive surgery (CRS); "cytoreduction" refers to reducing the number of tumor cells. Debulking is used with curative intent in only some types of cancer, as generally partial removal of a malignant tumor is not a worthwhile intervention for curative purposes (because malignant cells left behind soon multiply and renew the threat). Ovarian cancer and some types of brain tumor are debulked before radiotherapy or chemotherapy begin, making those therapies more effective. It may also be used in the case of slow-growing tumors to shift tumor cells from phase of cell cycle to replicative pool. In other types of cancer where debulking is not curative, it is sometimes done with palliat ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cisplatin
Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, breast cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein. Common side effects include bone marrow suppression, hearing problems, including total irreversible hearing loss, usually restricted to one ear, kidney damage, and vomiting. Other serious side effects include numbness, trouble walking, allergic reactions, electrolyte problems, and heart disease. Use during pregnancy can cause harm to the developing fetus. Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its replication. Cisplatin was discovered in 1845 and licensed for medical use in 1978 and 1979. It is on the World Health Organization's List of Essential Medicines. Medical use Cisplatin is a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Irinotecan
Irinotecan, sold under the brand name Camptosar among others, is a medication used to treat colon cancer, and small cell lung cancer. For colon cancer it is used either alone or with fluorouracil. For small cell lung cancer it is used with cisplatin. It is given intravenously. Common side effects include diarrhea, vomiting, bone marrow suppression, hair loss, shortness of breath, and fever. Other severe side effects include blood clots, colon inflammation, and allergic reactions. Those with two copies of the UGT1A1*28 gene variant are at higher risk for side effects. Use during pregnancy can result in harm to the baby. Irinotecan is a topoisomerase inhibitor—it blocks the topoisomerase I enzyme, resulting in DNA damage and cell death. Irinotecan was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is made from the natural compound camptothecin which is found in the Chinese ornamental tree ''Campt ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Uterine Clear-cell Carcinoma
Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is aggressive and has high recurrence rate. Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather it arises from an atrophic endometrium. Such lesions belong to the type II endometrial cancers. Diagnosis The lesion is found in patients who present typically with abnormal or postmenopausal bleeding or discharge. Such bleeding is followed by further evaluation leading to a tissue diagnosis, usually done by a dilatation and curettage (D&C). A work-up to follow would look for metastasis using imaging technology including sonography and MRI. The median age at diagnosis in a large study was 66 years. Histologically the lesion may coexist with classical endometrial cancer. Treatment Prognosis of the CC is affected by age, stage, and histology as well as treatment The primary treatment is ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
